Iterum Therapeutics plc: A Major Update

If you have followed Iterum Therapeutics since its FDA approval news, this update marks a complete reversal of that story.

1. What happened?

Iterum Therapeutics has filed a petition in the Irish High Court to wind up the company. In plain English, the company is shutting down and selling off its assets. The court appointed Tom O’Brien and James Anderson from Teneo Restructuring as "Joint Provisional Liquidators." Think of them as the people brought in to turn off the lights, sell the furniture, and pay off the company's debts.

2. Why is this happening?

Although the company received FDA approval for its drug, ORLYNVAH™, on October 25, 2024, it could not afford to bring the product to market. The company faced a "perfect storm" of problems:

• Running out of cash: The company’s cash reserves were too low to fund operations, and its quarterly expenses far exceeded its minimal revenue.
• No way to raise money: Shareholders rejected a vote on November 14, 2024, to authorize more shares. This removed the company’s main way to raise cash for the ORLYNVAH™ launch.
• Failed deals: The company tried to find a buyer or a licensing partner but received no offers that could cover its $45 million in debt.
• High costs: Building a sales force and scaling up manufacturing proved too expensive to sustain without new funding.

3. What does this mean for the stock?

The company warns that shareholders could lose their entire investment.

• Trading: Nasdaq is moving to delist the stock. Once this happens, trading will likely move to the Over-the-Counter (OTC) markets, where the stock will be harder to trade and more volatile.
• The "Pecking Order": When a company liquidates, creditors—specifically those holding the company's $45 million in debt—get paid first. Because the company’s debts exceed the value of its assets, shareholders will likely receive nothing.
• Leadership: The liquidators now control the company, not the original management team.

4. What about the drug, ORLYNVAH™?

The drug’s future is uncertain. The liquidators may withdraw ORLYNVAH™ from the U.S. market because the costs of maintaining it outweigh the potential revenue. The company is unlikely to pursue further development or sales.

5. What happens next?

The court will hear the petition on April 13, 2026. If approved, the liquidators will become permanent. They will then sell the company’s intellectual property and patents to pay back creditors.

If you have questions, contact the company at: Iterum.Liquidation@teneo.com.

The bottom line: The commercial success story has ended. Please exercise extreme caution. The risk of losing your entire investment is very high, as the company’s heavy debt must be paid before shareholders see any money. If you are currently holding shares, you should carefully consider whether the potential for any residual value justifies the high risk of a total loss.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.